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Mutations in the WTI tumor suppressor gene are known to  contribute to  the development of Wilms’ tumor (WT) and 
associated gonadal abnormalities. WTI is expressed principally in the fetal kidney, developing gonads, and spleen and also in the 
mesothelium, which lines the coelomic cavities. These tissues develop from mesenchymal components that have subsequently 
become epithelialized, and it has therefore been proposed that WTI may play a role in this transition of cell types. To test the 
possible involvement of this gene in malignant mesothelioma, we have f i r s t  studied i ts  expression in a panel of human normal 
and malignant mesothelial cell lines. WTI mRNA expression levels varied greatly between the cell lines and no specific 
chromosomal aberration on I I p, which could be related to  the variation in WTI expression in these cell lines, was observed. 
Furthermore, no gross deletions, rearrangements, or functionally inactivating point mutations in the WTI coding region were 
identified. All four WTI splice variants were observed a t  similar levels in these cell lines. The WTI gene encodes a zinc-finger 
transcription factor and the four protein isoforms are each believed to  act as transcriptional repressors of certain growth factor 
genes. Lack of W7b expression is thus predicted to  result in growth stimulation of tumor cells. Binding of one particular WTI 
isoform construct to the insulin-like growth factor 2 (IGFZ) and platelet-derived growth factor A (PDGFA) gene promoters has 
been demonstrated to  result in repression of these genes in transient transfection studies. Analysis of IGF2 and PDGFA mRNA 
expression levels compared with WTI mRNA expression levels failed t o  demonstrate an inverse correlation in the mesothelial 
cell lines, which endogenously express these genes. Finally, the putative role of WTI in the transition of cell types was 
investigated. No obvious correlation between WTI expression levels and cell morphology of the malignant mesothelial cell lines 
was evident from this study. Moreover, no change in WJI expression was observed in normal mesothelial cells which were, 
by alteration of culture conditions, manipulated to  switch from the mesenchymal to epithelial morphology. Genes Chromosom 
Cancer 12:87-96 (1995). 0 1995 Wiley-Liss, Inc. 
INTRODUCTION 
Human malignant mesothelioma is a mesoder- 
mally derived tumor, which is most often found in 
the pleura. Its incidence is strongly associated with 
exposure to asbestos fibers (Wagner et al., 1960). 
Malignant mesothelioma is thought to develop 
from mesothelial cells, which form a specialized 
epithelium lining the coelomic cavities. Malignant 
mesothelioma was mentioned as one of the so- 
called second risk tumors in a few patients who had 
recovered from the pediatric kidney malignancy 
Wilms’ tumor (WT) (Austin et al., 1986). This sug- 
gests the possible involvement of a common un- 
derlying genetic event in both malignancies. 
T h e  WTI locus on l l p13  has been identified as 
one of the chromosomal loci contributing to W T  
development (Call et al., 1990; Gessler et al., 
1990). WTI encodes a protein with DNA-binding 
capacity, elicited by four zinc-fingers at the C-ter- 
minal part, which bind to DNA sequences with the 
core consensus element 5’-GCGGGGGCG-3’ 
(Rauscher et al., 1990). T h e  WT1 protein addi- 
tionally possesses transcriptional regulatory activity 
exerted through the N-terminal glutamine- and 
proline-rich regions of the protein (Madden et al., 
1991). Alternative splicing of the W71 gene at two 
independent splice sites has been shown to result 
in the formation of four UrTI splice variants. In 
tumor tissue and fetal kidney there appears to be 
little variation in the ratios of these four isoforms 
(Haber et al., 1991; Brenner et al., 1992). 
In transient transfection studies insulin-like 
growth factor 2 (IGFZ), platelet-derived growth 
factor A (PDGFA), and IGFIR have recently been 
identified as potential target genes for transcrip- 
tional repression by WT1 (Drummond et al., 1992; 
Gashler et at., 1992; Wang et al., 1992; Werner et 
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al. ,  1993). These  and other results have led to the 
hypothesis that the WT1 protein functions as a 
tumor suppressor gene product and that reduction 
or absence of WTI expression that is seen in a pro- 
portion of WTs  results in an increased expression 
of certain growth factor genes. However, transac- 
tivation by WT1 was also seen, depending on the 
presence of wild-type TP53  protein, the number of 
WT1 binding sites in the promoter of the target 
gene, or the presence of specific missense muta- 
tions within the transregulatory domain (Ma- 
heswaran et al., 1993; Park et  al., 1993a; Wang et 
al., 1993). 
Despite these results on repression or activation 
of certain target genes by WT1 in transient assays, 
not much is known about the physiological role of 
WT1. It  has been suggested that WT1 may play a 
role in mediating the shift from a mesenchymal to 
an epithelial phenotype, as i t  is expressed in the 
nephrogenic epithelia, in epithelial cells of the go- 
nads, and in the mesothelium (Pritchard-Jones et 
al., 1990; Pelletier et al., 1991; Armstrong et al., 
1992). These  are all cells of mesodermal origin that 
have undergone t h e  transition to the epithelial 
morphology. However, other cell types undergoing 
this transition do  not express the WTI gene, 
whereas in embryonic mice distinct regions in the 
spinal cord and brain that are of ectodermal origin 
display WTI expression, arguing that there should 
be other tissue-specific roles for W T I  in develop- 
ment (Armstrong et al., 1992). Recently, a crucial 
role for WT1 in early urogenital development was 
established in a model system by gene targeting in 
murine embryonic stem cells (Kreidberg et al.,  
1993). In these WTI knockout mice a failure in 
kidney development was observed. This  was sug- 
gested to be caused by inhibition of inductive 
events leading to the formation of the metanephric 
kidney. In addition, abnormal development of the 
gonads, the heart, and the mesothelium was seen 
as well. Abnormalities in the phenotypes of these 
tissues support the idea of a role for W T 1  in the 
mesenchymal to epithelial cell transition. 
As WTI expression was observed in the human 
and mouse developing and mature mesothelium 
(Pritchard-Jones et al., 1990; Armstrong et al., 
1992; Park et al., 1993b), we were interested to 
determine whether WTZ was also expressed in its 
malignant counterpart as this might indicate a pos- 
sible involvement of WTI in the pathogenesis of 
malignant mesothelioma. In this respect, it is 
worth noting that cytogenetic analysis of 40 con- 
firmed mesothelioma patients revealed karyotypic 
abnormalities in several chromosomes, but only in 
a few cases were rearrangements in l l p  seen 
(Hagemeijer et al., 1990). We have studied expres- 
sion of the WTZ gene in a panel of human normal 
and malignant mesothelial cell lines. Expression 
levels were related to the morphology (epithelial or 
mesenchymal) of the mesothelioma cells in vitro in 
order to clarify putative WT1 involvement in cell 
type transition. We also investigated whether gross 
alterations or point mutations could be detected at  
the WTI locus, whether the four different alterna- 
tively spliced mRKAs were present in the various 
normal and malignant mesothelial cell lines, and 
whether the WTI mRNA expression level in these 
cell lines could be correlated to their PDGFA and 
ZGFZ mRNA levels. 
MATERIALS AND METHODS 
Cell Lines, Growth Conditions, Characterization, 
and Cytogenetics 
Experiments were performed using the human 
pleural malignant inesothelioma cell lines Mero- 
and -123 (Versnel et al., 1988, 1989) and the nor- 
mal mesothelial cell lines Nh4-1, -4, -5, -9, and -12 
(Versnel et  al., 1991, 1993; Langerak et al., in 
preparation). All mesothelioma cell lines were de- 
rived from mesothelioma patients whose diagnosis 
was based on routine cytology, which was histolog- 
ically or ultrastructurally confirmed. Cell lines were 
routinely cultured as described earlier (Versnel et 
al., 1988, 1989). Cytogenetic analysis was per- 
formed as described earlier (Versnel et al., 1988). 
14, -25, -41, -48b, -48c, -72, -82, -83, -84, -95, -96, 
Northern and Southern Blot Analyses and Probes 
Northern blotting and Southern blotting were 
performed as described in Langerak et al. (1992). 
For hybridization of Northern and Southern blots 
a 1.8 k b  EroRI WTI fragment derived from the 
WT33 cDNA was used (Call et al., 1990). North- 
ern blots were rehybridized with the  1.3 k b  EroRI 
PDGFA fragment (Betsholtz et  al., 1986), the 1.4 
kb XbaI-EcoRI ZGFZ fragment from pIGF-I1 (Jan- 
sen et al., 1985), and the 0.7 kb  EroRI-PstI glyc- 
eraldehyde-3-phosphate dehydrogenase (GAPDH) 
fragment (Benham et al., 1984). Rehybridization of 
Southern blots was performed with a 1.3 k b  PuI 
ZGFZ fragment from pKT218 (Jansen et al., 1985). 
Reverse Transcription (RT) Polymerase Chain 
Reaction (PCR) Analysis 
R T  of RNA, isolated from the normal and ma- 
lignant mesothelial cell lines, and subsequent PCR 
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analysis were performed as described previously 
(Langerak et al., 1992). For amplification of the 
alternative splice variants the sense primers B297 
(5 ' -TTG GTC, GAC ATG ACC TGG AAT 
CAG/C ATG-3';  located in WTl exon 4) or B439 
(5 ' -CTT GTA (CGG T C G  GCA TCT-3 ' ;  located 
in bVT1 exon 7) were used in combination with 
antisense primer B298 (5'-TGC AAG CTT CAG 
C T G  AAG GGT/C T T C / T  TC-3';  located in U'Tl 
exon 10) (Little et al., 1992). Thirty-five cycles of 
1 rnin at 94"C, I rnin at 5O"C, and 2 rnin at 72°C 
were performed. PCR products were analyzed on 
10% polyacrylamide gels using PstI digested 
lambda DNA a:; a marker. 
Point Mutation Analysis 
Chemical cleavage mismatch analysis using hy- 
droxylamine and osmium tetroxide ( H O T  analysis) 
was performed as described (Cotton et al., 1988; 
Prosser et al., 1990). Templates were generated by 
RT-nested PCR (Hanson et al., 1993), a strategy 
required due  to low yields of available RNA. The 
IVfl region encoding the transregulatory domain 
was amplified with outer primers D609 sense (5'- 
CAA ACA GGA GCC GAG C T G  G-3') and D610 
antisense (5'-GCA C A T  CCT GAA T G C  CTC 
TG-3') followed by inner primers 1 and 3 (Brown 
et al., 1992). The DNA-binding domain was sim- 
ilarly amplified with primers C582 sense (5'-AAA 
T G G  ACA GAA G G G  CAG AGC-3') and C583 
antisense (5'-T'TG GAA G T T  GGA T G A  AGA 
AGA TC-3') followed by primers 2 and 4 (Brown et 
al., 1992). PCR conditions for D609/D610 are step 
1, 1 min at 94°C:; step 2, 30 cycles of 30 sec at 94"C, 
1 min at 54"C, and 1-2 rnin at 72°C; step 3, 10 min 
at 72°C. Touchdown PCR conditions for C582/ 
C583 are step 1, 1 rnin at 94°C; step 2 ,  30 cycles of 
30 sec at 9Z"C, 1 rnin at 62-57°C and 2 rnin at 
72°C; step 3, 110 min at 72°C. Samples generating 
cleaved fragments after H O T  analysis were sub- 
jected to a second round of RT-nested PCR. T h e n  
the products were purified by P-Agarase I (New 
England Biolabs, Beverly, hlA) and subsequently 
sequenced directly as described (Winship, 1989). 
RESULTS 
WTI mRNA Expression in Mesothelial Cell Lines 
Expression of the WTl gene was studied on 
Northern blots, containing total RNA from normal 
and malignant rnesothelial cell lines of human ori- 
gin. WTl m R h A  was found to be consistently ex- 
pressed in the normal mesothelial cell lines, al- 
though some variation in the levels was observed 
(Fig. 1). T h e  WTl expression level was highly vari- 
able in the investigated panel of malignant me- 
sothelioma cell lines, ranging from very high 
(blero-25) to nearly or totally undetectable (h4ero- 
41, -72, -82, -83, -95) (Fig. 1). WTl niRNA expres- 
sion levels were normalized over GAPDH mRNA 
levels after quantification by densitometric analysis 
(see Table 1). 
Based on their histology, malignant mesothelio- 
mas can be classified as epithelial, mesenchymal, 
or biphasic. T h e  morphology of the cultured me- 
sothelioma cells in monolayer can differ from the 
primary tumor-tissue morphology (see Table 1). In 
an attempt to clarify the possible role of the IVTl 
gene product in the transition of certain cell types 
from a mesenchymal toward an epithelial morphol- 
ogy, WTl mRNA expression levels in the cultured 
niesothelioma cells were therefore related to the 
epithelial or fibrous/mesenchymal morphology of 
these cell lines. Although the highest WTl mKNA 
level was observed in htero-25, which has the 
clearest epithelial phenotype, WTl expression was 
not completely confined to cell lines showing an 
epithelial or biphasic morphology. LVTl mRNA was 
undetectable in several cell lines with a fibrous 
morphology like Mero-41 and -72, but other fi- 
brous cell lines did express WTl (Mero-83, -96, and 
-123). In cell lines that were predominantly either 
fibrous or epithelial, expression was observed oc- 
casionally (Mero-48b, -48c, and -84), and in others 
not at all (Mero-82 and -95). 
T h e  putative involvement of WTl in the mesen- 
chymal to epithelial shift was further studied using 
a second approach. It has been described that cul- 
tured normal mesothelial cells can adopt a mesen- 
chymal (fibrous) or epithelial cell shape depending 
on the presence or absence of epidermal growth 
factor (EGF) in the culture medium, respectively 
(Connell and Rheinwald, 1983). Therefore, the 
WTl mRNA level was determined in two normal 
mesothelial cell lines under these conditions. T h e  
two cell lines showed a more epithelial morphology 
upon removal of E G F  [and hydrocortisone (HC)]  
for 3 days from the standard culture medium. How- 
ever, analysis of RNA isolated from the mesothelial 
cells cultured for 72 hr in the absence of EGF and 
H C  did not result in a significantly altered level of 
WTl mRNA (data not shown). 
Alternative Splicing Pattern of WTI 
T h e  U'Tl gene is capable of producing four dif- 
ferent mRNAs by alternative splicing, which can 
lead to the insertion of an extra 51 bp  (exon 5) 
upstream of the zinc-fingers and/or 9 bp (giving rise 
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Figure I. Northern blot analysis with 25 pg total RNA from normal (NM) and malignant (Mero) 
mesothelial cell lines. RNA was hybridized to WTI and GAPDH probes. 
TABLE I. Summary of Cytogenetics, Tumor Cell Line Morphology, and WTI Expression in Normal (NM) and Malignant (Mero) 
Mesothelial Cell Lines 
WTI gene WTI Modal No. of copies of chromosome (arm) 
Tumor chromo- WTI structure WTI mRNA 
cell line some Normal Rearranged Total mRNA (Southern gene (alternative 
Cell line morphology No. No. I I No. I I p  No. I I p  levela blot) (mutations) splicing) 
NM- I - 
NM-4 - 
NM-5 - 
NM-9 - 
NM-12 - 
Mero- I 4  Fibrous 
Mero-25 Epithelial 
Mero-4 I Fibrous 
Mero-48a Epithelial 
(fibrous)d 
Mero-48b Fibrous 
(epithelial) 
Mero-48c Fibrous 
(epithelial) 
Mero-72 Fibrous 
Mero-82 Fibrous 
Mero-83 Fibrous 
Mero-84 Fibrous 
Mero-95 Biphasic 
Mero-96 Fibrous 
Mero- I23 Fibrous 
(epithelial) 
(epithelial) 
46 
46 
46 
46 
46 
75 
67 
72 
7 1-75 
71-75 
71-75 
42 
49 
75-85 
38 
54-58 
72-78 
55 
2 
2 
2 
2 
2 
3 (4) 
3 (4) 
4 
3 
3 
3 
2 
2 
2 
0 
3 
3 
2 (3) 
- 
- 
- 
- 
- 
- 
I x inv ( I  I)(pl lq14) 
I x mar (t(9p; I I p)) 
- 
I x mar (t(9p; I I p)) 
I x mar (t(9p; I I p)) 
2xadd I lp15 
t(6p + ;I lp-). 
+der( I I)t( I 1;22) 
- 
2X6q-(6p::I Ip) 
- 
2 
2 
2 
2 
2 
3 (4) 
4 (5) 
4 
4 
4 
4 
2 
2 
4 
2 
3 
3 
4 (5) 
0.81 N D ~  
0.28 N D  
0.12 N D  
0.26 Normal 
0.08 N D  
0.04 Normal 
9.59 Normal 
0 Normal 
N D  Normal 
0.43 Normal 
0.12 Normal 
0 Normal 
0 Normal 
0.04 Normal 
0.14 Normal 
0 Normal 
0.26 Normal 
0.91 N D  
ND 
ND 
ND 
ND 
ND 
Not found 
Not found 
ND 
Not found 
Neutral 
transition 
Neutral 
transition 
ND 
ND 
Not found 
Not  found 
ND 
Not found 
Neutral 
transition 
4 isoforms 
ND 
ND 
ND 
ND 
4 isoforms 
4 isoforms 
NA' 
ND 
ND 
4 isoforms 
N A  
N A  
4 isoforms 
4 isoforms 
N A  
4 isoforms 
4 isoforms 
"Shown over GAPDH expression levels as determined by densitometry 
bND, not determined. 
'NA, not applicable. 
parentheses: minority of the cells. 
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Figure 2. RT PCF: analysis with RNA from malignant mesothelioma 
cell lines Mero- I 4  and -25 and normal mesothelial cell line NM- I. WT33 
cDNA was used as a positive control (+ ). In the left lane Pstl digested 
lambda DNA was loaded as a size marker. 
to the KTS amino acid sequence) between zinc- 
fingers 3 and 4 (Haber et al., 1991; Brenner et al., 
1992). In this study the occurrence of these distinct 
WTZ mRNA forms was examined in clonal cell 
lines. For this purpose cDNA derived from total 
RNA of several of the WTZ expressing malignant 
mesothelioma cell lines (see Table 1) was used in a 
PCR reaction with primers B297 and B298. Four 
distinct DNA fragments of 499 bp (-51 bp, 
bp, -KTS), and 559 bp ( +  51 bp, + KTS), result- 
ing from two independent alternative splicing 
events, were observed (see Table 1). All four splice 
variants were detected in normal mesothelial cell 
line NM-1 as well. In Figure 2 these results are 
shown for the cell lines NM-1 and Mero-14 and 
-25. Using primers B439 and B298 in all cell lines 
studied, two distinct fragments of 320 and 329 bp 
were seen, whiich result from the 9 bp alternative 
splicing event (data not shown). In our WTZ 
mRNA expressing mesothelial cell lines, little vari- 
ation was observed in the ratios of the four iso- 
forms. 
-KTS), 508 bp (-51 bp, +KTS), 550 bp ( + 5 1  
Cytogenetic and Genomic Data Concerning WTI 
T h e  variation in WTZ mRNA expression that we 
observed in the malignant mesothelioma cell lines 
could be due to differences in the whole or partial 
copy number of chromosome arm l l p .  Further- 
more, rearrangements of the WTZ gene or gene 
amplification may also be involved. T o  see if any of 
these possibilities may explain the variation in WTZ 
mRNA level in the mesothelioma cell lines, cyto- 
genetic analysis and Southern blotting were em- 
ployed. 
Cytogenetic data from the mesothelioma cell 
lines were obtained by studying metaphase cells. 
Analysis of chromosome arm l l p  in the mesothe- 
lioma cell lines did not point toward any specific 
chromosomal aberration that could be correlated to 
their WTZ mRNA expression level (see Table 1). 
T h e  aneuploidy of chromosome arm l l p  and the 
WTZ mRNA level in the various cell lines did not 
correlate either (Table 1). 
T o  see if gene rearrangements had occurred in 
those cell lines showing very low or undetectable 
amounts of WTZ mRNA, the WTZ gene was stud- 
ied by Southern blot analysis. No differences were 
found in the EcoRI and Hind111 digestion pattern 
of DNA from any of the malignant mesothelioma 
cell lines studied compared to the pattern of nor- 
mal mesothelial cell line NM-9 (Fig. 3; also data 
not shown). This indicated that gross rearrange- 
ments in the WTZ gene had not occurred in the 
malignant mesothelial cell lines and thus were not 
likely to be the cause of undetectable WTZ mRNA 
expression in Mero-41, -72, -82, and -95. 
By Southern blot analysis we did detect small 
differences in the intensity of the bands for the 
various cell lines, which could in principle be 
caused by variation in the number of WTZ gene 
copies. However, rehybridization of the filter con- 
taining Hind111 digested DNA with a probe for the 
ZGFZ gene, which is also located on the short arm 
of chromosome 11 at l lp15, showed similar differ- 
ences in intensity (data not shown). This meant 
that the WTZ gene was not differentially amplified 
in any of the cell lines. Variation in the number of 
copies of 1 l p  may exist but in general the number 
of chromosome arm l l p  largely balanced the total 
chromosome number, which suggests that the 
small differences in intensity are most probably 
due to small variations in loading of the gels. 
WTI Point Mutation Analysis 
T h e  H O T  technique of chemical cleavage mis- 
match analysis was used to scan virtually the entire 
coding sequence of WTZ for point mutations. Only 
the first 256 bp in exon 1 were omitted from this 
analysis, as the high GC content of this region ren- 
ders it refractory to PCR amplification. T h e  malig- 
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Figure 3. Southern blot analysis of the WTI gene. EcoRI-digested genornic DNA from a normal (NM-9) 
and several malignant (Mero) rnesothelial cell lines was hybridized to  a '*P-labeled WTI probe. 
nant mesothelioma cell lines Mero-14, -48b, -48c, 
-83, -84, and -123 were scanned for point mutations 
in exons 1-6, encoding the transregulatory do- 
main, and R,lero-14, -25, -48b, -48c, -83, -84, -96, 
and -123 were scanned for point mutations in exons 
6-10, encoding the DNA-binding domain. T h e  
only base change detected was a novel C to T 
transition a t  nucleotide 768 (numbered according 
to Gessler et al., 1990). Th i s  exon 1 transition is a 
third base change and does not cause amino acid 
substitution (AAC/T encodes an Asn residue). It is 
present in the homo/hemizygous state in hlero- 
48b, -48c, and -123 (data not shown). No function- 
ally inactivating nonsense or missense mutations 
were detected (see Table 1). 
WTI mRNA Expression in Relation to PDGFA and 
IGFZ mRNA Expression 
In transient transfection assays WT1 was re- 
ported to repress the expression of PDGFA and 
IGFZ promoter constructs. In order to see if the 
described variation in WTZ mRNA expression in 
our mesothelial cell lines could be related to dif- 
ferent levels of PDGFA and IGF2 mRNA, blots 
were rehybridized with probes for these two genes 
and analyzed by densitometry. T h e  results from a 
representative experiment are presented as arbi- 
trary units over GAPDH signals in Table 2. 
TABLE 2. mRNA Expression Levels of WTI, PDGfA, 
and IGf2 (6.0 and 4.8 kb) in Normal (NM) and 
Malignant (Mero) Mesothelial Cell Lines, Expressed as 
Relative Densitometric Units Over GAPDH 
Expression Levels 
IGFZ 
Cell linea WTI PDGfAb 6.0 kb 4.8 kb 
NM- I 
NM-4 
NM-9 
NM-5 
NM-12 
Mero-25 
Mero- I23 
Mero-48b 
Mero-96 
Mero-84 
Mero-48c 
Mero- I 4  
Mero-83 
Mero-82 
Mero-72 
Mero-95 
Mero-41 
0.8 I 0.65 0 0.5 3 
0.28 0.78 0.19 0.66 
0.26 ND' 0 0.23 
0.12 0.62 0.12 0.48 
0.08 ND 0.23 0.48 
9.59 I .42 0 0.73 
0.91 2.22 0 0.68 
0.43 1.41 0.28 1.02 
0.26 3.74 1.72 6.55 
0.14 I .55 0.02 0.23 
0.12 0.50 0.29 0.43 
0.04 0.04 0 0.16 
0.04 1.18 0.0 I 0.18 
0 I .02 0 0.2 I 
0 2.59 2.37 2.62 
0 2.62 0.07 0.44 
0 7.54 0.24 I .27 
"Cell lines are arranged in descending order of WTI expression 
levels. 
bTotaled levels of 2.8, 2.3, and I .9 kb PDGFA transcripts. 
'ND, not determined. 
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Figure 4. Relative densitometric units of the mRNA expression lev- 
els of WTI, PDGFA (2.8, 2.3, and 1.9 kb totaled) and lGF2 (6.0 kb) in 
normal (NM) and malignant (Mero) mesothelial cell lines. The data are 
The densitometric data of the three PDGFA 
transcripts (2.8, 2.3, and 1.9 kb) were totaled, as 
expression of these three messengers is under con- 
trol of a single promoter region that contains con- 
sensus WT1 binding sequences. Our mesothe- 
lioma cell lines demonstrated variation in PDGFA 
mRNA expression, but in general the expression 
level was higher than in normal mesothelial cell 
lines. In a few cell lines lacking WTI mRNA, a 
relatively high PDGFA expression was seen (Mero- 
41, -72, and -%), but other cell lines which did 
show WTI mRNA expression, i.e., Mero-96 and 
-123, displayed a similar PDGFA mRNA level. Cell 
line Mero-25, in which a very high WTI mRNA 
level was seen, showed an intermediate level of 
PDGFA expression. This intermediate PDGFA 
level, however, was also seen in cell lines with a 
lower IVTI mRNA content than Mero-25. So, as is 
also illustrated in Figure 4, no clear correlation was 
observed between WTI and PDGFA expression in 
our mesothelial cell lines. 
T h e  6.0 kb 1’GFZ transcript is the product of the 
fetal P3 promocer, which contains W T l  consensus 
binding sequences, whereas the 4.8 kb transcript is 
expressed from a different fetal promoter (P4), also 
containing corisensus WT1 binding sequences. 
Relatively high IVTI mRNA levels were found in 
cell lines which do not express the 6.0 kb ZGF2 
transcript (NM- 1 and Mero-25 and -123), but other 
cell lines which demonstrated very low or no 6.0 kb 
ZGFZ mRNA expression, like NM-9 and hlero-14, 
-82, -83, -84, and -95, showed a low or intermedi- 
‘3 48b 96 84 48c 14 83 82 72 
Mero 
95 41 
presented on a log scale. See Table 2 for the exact densitometric units. 
Cell lines are arranged in descending order of WTI expression levels. 
Expression levels that were not determined are indicated by an asterisk. 
ate WTI mRNA level. In the panel of normal and 
mesothelial cell lines no clear relationship, recip- 
rocal or otherwise, was observed between the 6.0 
kb ZGFZ and WTI mRNA level (see also Fig. 4). 
T h e  same holds true for the expression level of the 
4.8 kb ZGFZ transcript. 
DISCUSSION 
T h e  W T  gene WTI on l lp13  acquired its name, 
as it  was originally mapped by deletion analysis of 
individuals with the WAGR (WT, aniridia, geni- 
tourinary abnormalities, and mental retardation) 
syndrome (Riccardi et al., 1978; van Heyningen et 
al., 1985). T h e  demonstration of constitutional and 
somatic intragenic deletions in the WTI gene in a 
proportion of W T  patients has confirmed that it is 
a W T  predisposition gene (Haber et al., 1990; 
Cowell eta]. ,  1991; Huff et al., 1991; Brown et al., 
1992; Tadokoro et al., 1992). In expression studies 
in human and mouse embryos the WTI gene was 
reported to be involved in normal genitourinary 
development (Pritchard-Jones et al., 1990; Arm- 
strong et al., 1992). Because of this limited spatial 
expression, WTI was suggested to be important in  
tissues which are of mesodermal origin and which 
undergo a mesenchymal to epithelial transition, al- 
though expression was also observed in the spinal 
cord and developing brain. In situ hybridization 
studies showed high WTI expression in the devel- 
oping Sertoli cells of the testis and granulosa cells 
of the ovary (Pelletier et al., 1991; Armstrong et 
al., 1992). 
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As the studies by Pritchard-Jones et  al. (1990) 
and Armstrong et al. (1992) had revealed the ex- 
pression of WTI in the mesothelium, a specialized 
epithelium lining the coelomic cavities, an obvious 
question was if expression of the WTZ gene could 
be detected in mesothelioma as well. This  
prompted us to study WTI expression in a panel of 
normal and malignant human mesothelial cell 
lines. Northern blot analysis revealed the consis- 
tent presence of WTZ mRNA in cultured normal 
mesothelial cells, whereas in cultured malignant 
mesothelioma cells a variation in the expression 
level, ranging from very high to undetectable, was 
seen. We also found that the apparent lack of WTI 
mRNA expression in several of these cell lines 
probably was not due  to deletions or rearrange- 
ments in the WTZ gene. Furthermore, differences 
in the WTI mRNA expression level between dif- 
ferent cell lines could not be accounted for by gene 
amplification or a specific chromosomal aberration 
on l l p .  Differences in transcription initiation or 
RNA degradation thus most probably account for 
the variation in WTZ mRNA expression between 
the malignant mesothelioma cell lines. 
When the WTZ-expressing malignant mesothe- 
lioma cell lines were analyzed for more subtle al- 
terations within the coding sequence, no nonsense 
or missense mutations were found. Three  lines 
contained an identical C to T transition in the se- 
quence encoding the transregulatory domain. 
However, this mutation is predicted to be silent at  
the protein level and therefore most likely patho- 
logically insignificant. Recently a homozygous 
WTI missense mutation that alters a Ser residue in 
the transregulatory domain has been reported for a 
single case of human peritoneal mesothelioma 
(Park et al., 1993b). This  case is unusual in that the 
mesothelioma was not asbestos-related and was not 
actually a malignant tumor but rather a develop- 
mental abnormality. In addition, Park et al. 
(1993b) found no WTZ mutations in 32 specimens 
of asbestos-related mesothelioma. For our samples 
it is possible that there are undetected WTZ muta- 
tions in the 5’-most coding region of exon 1 or in 
the untranslated or intronic sequences of the gene. 
T h e  cell lines that fail to show WTZ mRNA expres- 
sion may additionally have mutations in the pro- 
moter/control regions of the gene. Differences in 
the occurrence of the four alternative splicing prod- 
ucts, which may result in altered specificity for 
DNA binding sites (Bickmore et al., 1992), were 
not observed in our panel of WTI expressing me- 
sothelial cell lines. All four variants were identified 
earlier in W T  tissue and in fetal kidney (Haber et 
al., 1991; Brenner et al., 1992). In these tissues the 
transcripts with the 9 bp alternative splice were 
suggested to be slightly predominant, whereas in 
our mesothelial cell lines we did not observe this, 
but a more quantitative assay has to be performed 
to unravel this putative discrepancy. 
Taken  together, the results obtained in our 
panel of malignant mesothelioma cell lines thus 
suggest that the WTZ gene may play a role as a 
tumor suppressor gene in a minority of human me- 
sotheliomas. T o  test this in vivo, we started to 
study primary tumor material from mesothelioma 
patients. WTI mRNA expression could be ob- 
served in cells from pleural effusions of four ma- 
lignant mesothelioma patients (data not shown). 
These  pleural fluids, however, contain tumor cells 
in combination with several other cell types, which 
means that this expression cannot be simply attrib- 
uted to tumor cells, even though pleural fluids 
with a high percentage of mesothelioma cells were 
analyzed. Immunofluorescence staining with WT1 
antibodies and/or RNA in situ hybridization would 
be more informative in this respect. 
As the ovarian surface epithelium is considered 
to be a specialized mesothelium (Papadaki and 
Beilby, 1971) and several ovarian carcinoma cell 
lines demonstrated a comparable PDGFA and 
PDGFB mRNA expression to malignant mesothe- 
lioma cell lines (Versnel et al., 1994), we  also an- 
alyzed several ovarian carcinoma cell lines for WTZ 
mRNA expression. Comparable to the expression 
i n  malignant mesothelioma cell lines, in three of 
six serous ovarian carcinoma cell lines studied, 
WTZ expression was observed on Northern blots, 
while in the  other three no WTI transcripts were 
detected (data not shown). Furthermore, we re- 
cently observed a very high WTZ mRNA level in 
cell line COV-434, which is derived from a granu- 
losa tumor of the ovary and thus is not of mesothe- 
lial origin (data not shown). This  expression is in 
agreement with the observed WTZ expression in 
ovarian granulosa cells (Armstrong et al., 1992). 
Malignant mesotheliomas are classified as epi- 
thelial, fibrous/mesenchymal, or biphasic. We 
therefore tried to correlate the morphology of the 
various malignant mesothelioma cell lines with 
their U’TZ mRNA expression level. Although the 
highest expression was found in cell line Mero-25, 
which has the most obvious epithelial morphology, 
no clear correlation could be observed between 
WTI mRNA expression and morphology. More- 
over, normal mesothelial cells which can switch in 
morphology depending on the addition or removal 
of EGF from the culture medium, showed similar 
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W7’1 expression levels independent of the pheno- 
type of the cell:j. So in these mesothelial cell lines 
no evidence could be found for a WT1 role in the 
mesenchymal to epithelial transition of cells. How- 
ever, this may be different in vivo. Therefore, me- 
sothelioma tissue from patients with a biphasic 
(i.e., with mesenchymal and epithelial elements) 
malignant mesothelioma should be studied with 
WT1 antibodies or by RNA in situ hybridization to 
investigate the putative correlation between WTI 
expression and morphology in vivo. 
It has been shown in transient transfection assays 
that WT1 represses PDGF’4 (Gashler et at., 1992; 
Wang et at., 1’392) and IGFZ mRNA expression 
(Drummond et at., 1992). Our panel of normal and 
malignant mesclthelial cell lines showing variation 
in WTI mRNA expression was analyzed for PDGFA 
and IGF,? mRNA levels as well. No clear relation- 
ship, reciprocal or otherwise, between U’TZ and 
PDGFA or IGF.? expression was found in our cell 
lines. T h e  fact that no clear correlation could be 
found in cells endogenously expressing these 
genes is in contrast with the repression seen in the 
forementioned studies. However, these data were 
obtained in cells upon transfection of WTI expres- 
sion constructs 1:ogether with PDGFA and IGF2 re- 
porter construci:s, whereas we looked at endoge- 
nous expression levels in a panel of cell lines. I t  
may also be that in our mesothelial cell lines other 
factors are also involved i n  regulating PDGFA and 
IGF2 mRNA expression, thereby masking regula- 
tion by WT1. Alternatively, mutations in the W T l  
binding sequences in the promoters of these genes 
may prohibit W T 1  regulation. I t  remains to be de- 
termined, whether W T l  can regulate expression of 
these genes in ;I physiological context. Evidence 
for this may come from stable transfection of the 
W i l  gene in Mero cell lines lacking WTI or knock- 
ing out the endogenous WTI gene expression in 
W77 expressing cell lines. 
In summary, we have shown that WTI mRNA is 
consistently expressed in normal mesothelial cell 
lines and that there is no expression in a minority of 
malignant mesothelioma cell lines. No indications 
were found for chromosomal aberrations, dele- 
tions, rearrangements, functionally inactivating 
missense or nonsense mutations, or an aberrant al- 
ternative splicing pattern in these cell lines. T h e  
\VTI expression level does not seem to correlate 
with the mesenchymal or epithelial morphology of 
the various cell lines in vitro. N o  inverse correla- 
tion between L‘C‘TI and PDGFA or IGFZ mRNA 
expression was x e n  in our panel of mesothelial cell 
lines, which endogenously express these genes. 
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